TC
ASND icon

Telemus Capital’s Ascendis Pharma A/S ASND Stock Holding History

Telemus Capital’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,000
Closed -$235K – 374
2019
Q1 		$235K Buy
+2,000
New +$175K 0.02% 373

Other funds holding ASND

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Telemus Capital's ASND Position: Q2 2019 in Review

Telemus Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2019, closing a stake of 2,000 shares — an estimated $235K sold.

Telemus Capital first reported a position in ASND in Q1 2019 and held it in 1 quarter. The position peaked at $235K in Q1 2019. 132 funds tracked by Wall St. Rank hold ASND as of Q2 2019.

  • Telemus Capital reported no remaining Ascendis Pharma A/S position as of Q2 2019 after selling out during the quarter.
  • Telemus Capital sold 2,000 Ascendis Pharma A/S shares in Q2 2019, an estimated $235K.
  • Telemus Capital first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 1 quarter.
  • Telemus Capital's Ascendis Pharma A/S position peaked at $235K in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2019.

Based on Telemus Capital's 13F filing for Q2 2019, filed 9 Aug 2019.